The Pharma Letter M&A roundup - November 2023

1 December 2023

Another month has passed into the annals of history, but not without note, so far as the pharmaceutical M&A world is concerned, thanks to the announcement of a major deal by AbbVie (NYSE: ABBV).

The Chicago-based drugmaker revealed this week that it was to acquire US antibody-drug conjugate specialist ImmunoGen (Nasdaq: IMGN) for the sizeable sum of around $10.1 billion.

Other big pharma companies that announced acquisitions were Astellas (TYO: 4503), Merck & Co (NYSE: MRK) and Boehringer Ingelheim, with overall pharma spending in M&A continuing to outpace both 2022 and 2021. Details of all the month's activity and more can be seen in the table and graphs below.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK